A simplified model to understand the targeted disease-modifying anti-inflammatory drugs

Ugeskr Laeger. 2024 Aug 12;186(33):V12230795. doi: 10.61409/V12230795.
[Article in Danish]

Abstract

This review presents a simplified model to understand better how disease-modifying anti-inflammatory drugs (DMAIDs) work in immune-mediated inflammatory diseases (IMIDs) with a focus on rheumatology, dermatology, and gastroenterology. In this model, IMIDs are listed on a spectrum from autoinflammatory to autoimmune characterised by the involvement of either mostly the innate or the adaptive immune system. DMAIDs specifically target these immune components and have shown efficacy in distinct IMIDs. DMAID classes include TNF blockers, IL-1 blockers, IL-6 receptor blockers, IL-17 blockers, IL-23 blockers, and janus kinase inhibitors.

Publication types

  • Review
  • English Abstract

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use
  • Autoimmune Diseases* / drug therapy
  • Autoimmune Diseases* / immunology
  • Humans
  • Inflammation / drug therapy
  • Inflammation / immunology

Substances

  • Anti-Inflammatory Agents
  • Antirheumatic Agents